Argenx stock gains support as Jefferies reiterates Buy rating

Published on 09/15/2026 at 14:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock remains backed by a Jefferies Buy rating with a USD 1,215 price target as of September 15, 2026. At the same time, recent conference comments highlight double-digit revenue growth and expanding margins.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock (ISIN NL0010832176) remains underpinned by positive analyst sentiment, with Jefferies reiterating its Buy rating and a price target of USD 1,215 as of September 15, 2026, according to wallstreetONLINE on September 15, 2026.

Jefferies sticks with Buy and high target

According to wallstreetONLINE on September 15, 2026, Jefferies has maintained its positive view on Argenx with a Buy rating and a price target of USD 1,215.

The same overview notes that Argenx shares were quoted at EUR 860.80 on Tradegate with a gain of 0.35% at 9:51 a.m. on September 15, 2026, indicating that the Jefferies stance comes against the backdrop of a solid recent performance in European trading, as reported by wallstreetONLINE on September 15, 2026.

Conference highlights revenue growth and cash position

Beyond the rating, Argenx has recently used the Morgan Stanley 24th Annual Global Healthcare Conference to outline its growth profile and financial strength, as reported on September 14, 2026 by Investing.com.

According to Investing.com, Argenx management said that VYVGART continued to drive growth, delivering 18 consecutive quarters of expansion since launch and achieving 17% sequential revenue growth from the first quarter to the second quarter of 2024.

The same conference commentary indicated that full-year 2024 revenue expectations from the market are around EUR 6,000,000,000, while operating margin expanded by more than 1,000 basis points over the past 12 months, with margins increasingly approaching the 40% range typical of larger biopharma groups, as summarized by Investing.com on September 14, 2026.

In addition, Argenx highlighted a cash position of EUR 5,200,000,000 at the end of the previous quarter, with approximately EUR 2,000,000,000 to EUR 2,200,000,000 used for the Forte acquisition, leaving significant financial flexibility for further pipeline and commercial investments, according to Investing.com.

Upcoming Q3 2026 results as next catalyst

Looking ahead, the next formal checkpoint for Argenx fundamentals is the publication of its third-quarter 2026 results, scheduled for October 22, 2026, according to the agenda section for Argenx on Zonebourse.

The same overview shows Argenx shares trading at EUR 862.40 on Euronext Brussels at around 10:40 a.m. on September 15, 2026, down 0.62% on the day but up 20.26% since the start of the year, while the last closing price of the Nasdaq listing was USD 1,001.50, with an average analyst price target of USD 1,179.34 implying 17.76% upside from that close, as presented by Zonebourse on September 15, 2026.

Stock positioning and investor takeaways

Based on the Nasdaq closing price of USD 1,001.50 and the average analyst target of USD 1,179.34, current consensus implies a potential gain of 17.76% if Argenx were to reach that level, according to Zonebourse.

For investors, the combination of Jefferies' high USD 1,215 target, consensus around USD 1,179.34 and management commentary about 17% sequential revenue growth and more than 1,000 basis points of margin improvement underscores that Argenx stock is currently priced with expectations of continued double-digit growth and further margin gains.

At the same time, the Morgan Stanley conference discussion highlighted that Argenx must continue to broaden beyond VYVGART and navigate competition and policy pressures in immunology, meaning that the strong balance sheet of EUR 5,200,000,000 and the investment in the Forte acquisition are important buffers against these risks, as emphasized by Investing.com on September 14, 2026.

Argenx stock price on Nasdaq

With Argenx listed on Nasdaq under the ticker ARGX, the reference price for the stock is the Nasdaq quote; the latest available closing price is USD 1,001.50 as of the most recent completed trading day shown in the analyst overview from Zonebourse, which also places that level below the average target of USD 1,179.34 by a margin of 17.76%.